Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for preclinical obesity drug LX9851.

Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA) therapy designed to lower the production of lipoprotein ...

The shooting of UnitedHealthcare CEO Brian Thompson in December rattled the industry and put healthcare CEOs in the spotlight in a way they were previously unaccustomed to. The months following ...

Not long ago, the FDA announced there's no longer a shortage of Ozempic, Wegovy, Zepbound or similar drugs used for weight ...

The high-profile Danish pharmaceutical company got a price-target cut from an analyst. That pundit remains lukewarm at best on the Wegovy maker's prospects. Well before market open that morning ...

Eli Lilly is expanding its menu of direct-to-consumer healthcare offerings. The Big Pharma announced Thursday that its LillyDirect platform will now connect U.S. users to both in-person and ...

The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli Lilly’s popular weight loss medication Zepbound and diabetes drug Mounjaro.

MG Motor India starts accepting pre-bookings for its premium CBU electric models, Cyberster and M9. Customers can book these models with a refundable token of Rs 51,000 at select dealerships and ...

Tirzepatide has been shown to help people lose more weight compared to semaglutide at the dosage regimens currently available ...